Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Company profile
Ticker
GLSI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
205473709
GLSI stock data
Latest filings (excl ownership)
8-K
Changes in Registrant's Certifying Accountant
20 Feb 24
8-K
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
14 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
15 Dec 23
DEFA14A
Additional proxy soliciting materials
25 Oct 23
ARS
2022 FY
Annual report to shareholders
24 Oct 23
DEF 14A
Definitive proxy
24 Oct 23
10-Q
2023 Q3
Quarterly report
19 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.14 mm | 9.14 mm | 9.14 mm | 9.14 mm | 9.14 mm | 9.14 mm |
Cash burn (monthly) | 600.21 k | 541.21 k | 834.31 k | 782.21 k | 600.21 k | 541.21 k |
Cash used (since last report) | 3.58 mm | 3.23 mm | 4.98 mm | 4.67 mm | 3.58 mm | 3.23 mm |
Cash remaining | 5.56 mm | 5.92 mm | 4.17 mm | 4.48 mm | 5.56 mm | 5.92 mm |
Runway (months of cash) | 9.3 | 10.9 | 5.0 | 5.7 | 9.3 | 10.9 |
Institutional ownership, Q2 2023
8.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 4.89 bn |
Total shares | 1.06 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Weiner Michael Guy | 429.69 k | $9.35 mm |
Vanguard | 282.22 k | $2.72 bn |
Renaissance Technologies | 79.20 k | $764.00 k |
AMP Ameriprise Financial | 68.19 k | $657.72 mm |
BLK Blackrock | 57.58 k | $555.31 mm |
Geode Capital Management | 39.93 k | $385.15 mm |
Millennium Management | 35.35 k | $340.93 mm |
Gsa Capital Partners | 33.41 k | $322.00 k |
STT State Street | 13.00 k | $125.40 mm |
HRT Financial | 10.14 k | $97.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Mar 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 19.98 | 2,500 | 49.95 k | 5,347,777 |
20 Mar 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 17.68 | 1,500 | 26.52 k | 5,345,277 |
5 Mar 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 12.49 | 30,500 | 380.95 k | 5,343,777 |
5 Mar 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 12.49 | 3,500 | 43.72 k | 5,343,777 |
4 Mar 24 | Snehal Patel | Common Stock | Buy | Acquire P | No | No | 13.03 | 4,100 | 53.42 k | 5,340,277 |
News
Insiders Buying Greenwich LifeSciences And 2 Other Stocks
25 Mar 24
HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $36 Price Target
28 Feb 24
Greenwich LifeSciences Flamingo-01 Phase 3 Trial Which Is Evaluating GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Approved to Expand Into Five Largest European Countries
27 Feb 24
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
22 Feb 24
HC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To Know
20 Feb 24
Press releases
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
13 Mar 24
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
12 Mar 24
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
22 Feb 24
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
14 Feb 24